Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2090-6226
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience ; volume:12 ; number:1 ; day:8 ; month:9 ; year:2022 ; pages:1-6 ; date:12.2022
Egyptian liver journal ; 12, Heft 1 (8.9.2022), 1-6, 12.2022

Urheber
Atef, Mira
Eletreby, Rasha
Abdallah, Mohamed
Salama, Rasha
Elakel, Wafaa
Hassany, Mohamed
Abdel-Razek, Wael
Shazly, Yehia El
Doss, Wahid
Esmat, Gamal
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s43066-022-00213-z
URN
urn:nbn:de:101:1-2022112521014234720014
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:38 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Atef, Mira
  • Eletreby, Rasha
  • Abdallah, Mohamed
  • Salama, Rasha
  • Elakel, Wafaa
  • Hassany, Mohamed
  • Abdel-Razek, Wael
  • Shazly, Yehia El
  • Doss, Wahid
  • Esmat, Gamal
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals

Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals

Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals

Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals

Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control

Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control

Impact of HCV eradication following direct-acting antivirals on liver stiffness measurement: a prospective longitudinal study

Impact of HCV eradication following direct-acting antivirals on liver stiffness measurement: a prospective longitudinal study

A systematic review of sofosbuvir/velpatasvir/voxilaprevir in HCV patients previously treated with direct-acting antivirals

A systematic review of sofosbuvir/velpatasvir/voxilaprevir in HCV patients previously treated with direct-acting antivirals

Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity

Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity

Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals

Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals

Proteomics reveals a global phenotypic shift of NK cells in HCV patients treated with direct‐acting antivirals

Proteomics reveals a global phenotypic shift of NK cells in HCV patients treated with direct‐acting antivirals

Direct-acting antivirals and visceral leishmaniasis: a case report

Direct-acting antivirals and visceral leishmaniasis: a case report

Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection

Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway

Verbundene Objekte